文献速递其他结缔组织病

荷兰DecreaSSc研究:通过家庭监测检测系统性硬化症相关间质性肺病患者肺功能下降的前瞻性观察研究

Detection of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease using home monitoring in the Netherlands (DecreaSSc): a prospective, observational study.
PubMed 文献 · Lancet Rheumatol · 2024-11-08

DecreaSSc是在荷兰两家三级转诊中心开展的前瞻性观察研究,纳入43例病程≤5年、高分辨率CT确诊间质性肺病、基线免疫抑制治疗≤8周的成人系统性硬化症患者,每周使用手持肺量计进行家庭肺量测定持续1年。家庭与医院测量检测用力肺活量百分比预测值下降≥5%的κ一致性为0.40(95%CI 0.01-0.79),家庭肺量测定的敏感度为60%(95%CI 44-76)、特异度为87%(95%CI 75-98)。

要点

  • 家庭肺量测定检测FVC%预测值下降≥5%的敏感度为60%、特异度为87%。
  • 家庭与医院测量判定FVC%预测值下降≥5%的一致性κ值为0.40(95%CI 0.01-0.79)。
  • 家庭与医院肺功能纵向相关系数为0.55(95%CI 0.26-0.74;p=0.0070)。

核心结论

  • 家庭肺量测定有潜力在常规医疗管理基础上更早检测系统性硬化症相关间质性肺病患者的肺功能下降。
  • 未来研究可能揭示家庭肺量测定是否有助于改善系统性硬化症相关间质性肺病患者的结局。

研究设计与样本

  • DecreaSSc是一项在荷兰两家三级转诊中心开展的前瞻性观察研究。
  • 纳入标准为年龄≥18岁、符合美国风湿病学会-欧洲抗风湿病联盟系统性硬化症分类标准、自首个非雷诺现象症状起病程≤5年、高分辨率CT确诊间质性肺病、基线时最大免疫抑制治疗时长≤8周。
  • 患者使用手持肺量计每周进行家庭肺量测定,持续1年;基线和每半年研究访视时在医院进行肺功能检测并完成患者报告结局问卷。
  • 主要结局为1年后家庭与医院测量检测用力肺活量(FVC)下降≥5%的κ一致性,采用对个体患者家庭和医院FVC%预测值分别进行线性回归分析估算。
  • 以医院肺功能检测为金标准,评估家庭肺量测定检测FVC%预测值绝对下降≥5%的敏感度和特异度。

主要发现

  • 2021年1月26日至2023年2月27日共纳入43例患者,其中35例完成6个月随访、31例完成12个月随访;末次随访于2024年3月28日进行。
  • 完成随访的患者中,20例(57%)为女性、15例(43%)为男性;32例(91%)为白人;平均年龄57.7岁(SD 10.7)。
  • 家庭与医院测量检测FVC%预测值下降≥5%的一致性κ值为0.40(95%CI 0.01-0.79)。
  • 家庭肺量测定检测FVC%预测值下降≥5%的敏感度为60%(95%CI 44-76),特异度为87%(95%CI 75-98)。
  • 回归分析显示医院与家庭评估的肺功能变化过程无差异,交互项不显著(-0.0003 [95%CI -0.0006至0.000008];p=0.057),纵向相关系数为0.55(95%CI 0.26-0.74;p=0.0070)。

临床怎么用

  • 原文结论认为家庭肺量测定有潜力在常规医疗管理基础上更早检测系统性硬化症相关间质性肺病患者的肺功能下降,未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In patients with systemic sclerosis, interstitial lung disease (ILD) is the leading cause of mortality. Early detection of progressive ILD associated with systemic sclerosis is warranted for timely adjustment of management strategies and improved prognosis. We aimed to investigate the validity of home spirometry to detect a decline in pulmonary function in patients with systemic sclerosis-associated ILD. METHODS: DecreaSSc was a prospective, observational study done in two tertiary referral centres in the Netherlands. Eligible patients were aged 18 years or older, fulfilled the American College of Rheumatology-European Alliance of Associations for Rheumatology criteria for systemic sclerosis, had a disease duration from first non-Raynaud phenomenon symptom of 5 years or less, had high-resolution CT-confirmed diagnosis of ILD, and had a maximum immunosuppressive treatment duration of 8 weeks at baseline. Patients took weekly home spirometry measurements using a handheld spirometer for 1 year. At baseline and at semi-annual study visits, patients pulmonary function testing was done in the hospital and patients completed questionnaires on patient-reported outcome measurements. The primary outcome was the κ agreement between home and hospital measurements after 1 year to detect a decline in force vital capacity (FVC) of 5% or more, estimated using separate linear regression analyses for home-based and hospital-based FVC% predicted in individual patients. The sensitivity and specificity of home spirometry to detect an absolute decline in FVC% predicted of 5% or more was assessed using the hospital pulmonary function test as the gold standard. The longitudinal correlation between hospital and home measurements was assessed with regression analysis, whereas the cross-sectional correlation was assessed with the intraclass coefficient. People with lived experience were involved at several stages of the study. FINDINGS: Between Jan 26, 2021, and Feb 27, 2023, 43 patients were enrolled, 35 of whom completed 6 months of follow-up and 31 of whom completed 12 months of follow-up. The last follow-up visit took place on March 28, 2024. 20 (57%) of patients were women and 15 (43%) were men; 32 (91%) were White. Mean age was 57·7 years (SD 10·7). The agreement between hospital and home measurements had a κ value of 0·40 (95% CI 0·01-0·79). The sensitivity of home spirometry to detect a decline in FVC% predicted of 5% or more was 60% (95% CI 44-76) and specificity was 87% (75-98). Regression analysis showed that the course of pulmonary function was not different between hospital and home assessment as the interaction term was not significant (-0·0003 [95% CI -0·0006 to 0·000008]; p=0·057) with a longitudinal correlation of 0·55 (95% CI 0·26-0·74; p=0·0070). The intraclass coefficient between both measurements was 0·85 (95% CI 0·73-0·92; p<0·0001) at baseline, 0·84 (0·71-0·92; p<0·0001) at 6 months, and 0·72 (0·50-0·86; p<0·0001) at 12 months. INTERPRETATION: Home spirometry has the potential to detect a decline in pulmonary function in patients with systemic sclerosis-associated ILD earlier when used in addition to regular health care management. Future research could reveal whether home spirometry can contribute to improved outcomes of patients with systemic sclerosis-associated ILD. FUNDING: Galapagos and Boehringer Ingelheim.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Velauthapillai A, Moor CC, de Vries-Bouwstra JK, et al. Detection of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease using home monitoring in the Netherlands (DecreaSSc): a prospective, observational study. Lancet Rheumatol. 2024. PMID: 39527968. doi:10.1016/S2665-9913(24)00236-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。